|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XC13
|
|
gptkbp:brand
|
gptkb:Perjeta
|
|
gptkbp:CASNumber
|
380610-27-5
|
|
gptkbp:chemicalFormula
|
C6530H10012N1736O2033S42
|
|
gptkbp:combinationTherapy
|
gptkb:trastuzumab
docetaxel
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Genentech
|
|
gptkbp:halfLife
|
18 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pertuzumab
|
|
gptkbp:immunogenicity
|
low
|
|
gptkbp:indication
|
HER2-positive metastatic breast cancer
early-stage HER2-positive breast cancer
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:ERBB2
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
inhibits dimerization of HER2 receptor
|
|
gptkbp:MedlinePlusID
|
a613032
|
|
gptkbp:monoclonalAntibodyType
|
humanized
|
|
gptkbp:notableCase
|
gptkb:CLEOPATRA_trial
gptkb:APHINITY_trial
|
|
gptkbp:patent
|
gptkb:Genentech
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinSequenceType
|
gptkb:IgG1_kappa
|
|
gptkbp:PubChem_CID
|
CHEMBL1201836
11708808
DB06616
|
|
gptkbp:riskOfCardiotoxicity
|
yes
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
alopecia
rash
neutropenia
infusion-related reactions
|
|
gptkbp:target
|
gptkb:HER2_receptor
|
|
gptkbp:UNII
|
45Y7D5L30P
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:usedInAdjuvantSetting
|
yes
|
|
gptkbp:usedInNeoadjuvantSetting
|
yes
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:Herceptin
gptkb:Perjeta
gptkb:APHINITY_trial
|
|
gptkbp:bfsLayer
|
6
|